CD274 and neoplasm: Our prediction model demonstrates superior accuracy in predicting immunotherapy response (AUC>0.7), outperforming traditional methods that rely solely on PD-L1 expression or tumor mutation burden (TMB) (Yarchoan et al., 2019).